An advisory committee of the US Food and Drug Administration (FDA) voted on Thursday to add the peptide BPC-157 to a drug compounding list.
FDA panel votes to add peptide BPC-157 to compounding list
The FDA’s advisory committee voted on Thursday to add BPC-157 to the drug compounding list.
Listen
Maksim Goncharenok
Updates
The FDA advisory committee also voted to permit the compounding of the peptide KPV. This decision to allow the compounding of unapproved peptides was reached by a narrow vote, reportedly amidst objections from FDA scientists regarding the loosening of restrictions.
In addition to BPC-157, the FDA advisory committee voted to allow compounding of the peptides KPV and TB-500. This series of narrow votes, which favor loosening restrictions on these unapproved and unproven substances, is being widely characterized as a significant political victory for RFK Jr. Reports indicate the committee reached these recommendations despite internal objections from FDA scientists, who warned that the safety and efficacy of these peptides remain unproven.
Sources 2
Spotted an error?
Report a correction.
